Open Payments

SUTTER SANTA ROSA REGIONAL HOSPITAL

Type
Teaching hospital
Where
SANTA ROSA, CA
Medicare CCN
050291
Received
$197,937 in 51 records, 2019 ($22,711 general, $175,225 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment16$22,711
2019Research payment35$175,225

By company

CompanyRecordsAmountYears
ABBVIE INC.19$113,2912019
Takeda Pharmaceuticals U.S.A., Inc.12$54,3782019
Zimmer Biomet Holdings, Inc.6$9,6972019
GENZYME CORPORATION3$7,0632019
Celgene Corporation2$5,6002019
SANOFI-AVENTIS U.S. LLC2$4,5002019
Janssen Pharmaceuticals, Inc1$1,5002019
Allergan, Inc.1$1,3922019
PENTAX of America, Inc.1$2482019
Siemens Medical Solutions USA, Inc.1$1992019
Olympus America Inc.3$662019

By nature of payment

NatureRecordsAmount
Research payment35$175,225
Space rental or facility fees (teaching hospital only)5$12,500
Gift10$10,012
Charitable Contribution1$199

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31Zimmer Biomet Holdings, Inc.$3,584GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-31Zimmer Biomet Holdings, Inc.$2,308GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-31Zimmer Biomet Holdings, Inc.$2,100GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-31Zimmer Biomet Holdings, Inc.$1,659GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-31PENTAX of America, Inc.$248Gift (2 payments)In-kind items and services Device, Gastroenterology2019
2019-12-31Siemens Medical Solutions USA, Inc.$199Charitable ContributionIn-kind items and services2019
2019-12-31Zimmer Biomet Holdings, Inc.$43GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-31Zimmer Biomet Holdings, Inc.$0GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-19ABBVIE INC.$9,167Research paymentCash or cash equivalentM18-9182019
2019-12-05ABBVIE INC.$2,880Research paymentCash or cash equivalentM14-3972019
2019-11-21ABBVIE INC.$7,217Research paymentCash or cash equivalentM18-9182019
2019-11-20ABBVIE INC.$540Research paymentCash or cash equivalentM14-2222019
2019-11-02GENZYME CORPORATION$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentLIBTAYO Drug, ONCOLOGY2019
2019-11-02GENZYME CORPORATION$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentELITEK Drug, ONCOLOGY2019
2019-10-30ABBVIE INC.$1,293Research paymentCash or cash equivalentM14-2222019
2019-10-21ABBVIE INC.$34,877Research paymentCash or cash equivalentM18-9182019
2019-10-12SANOFI-AVENTIS U.S. LLC$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentPRALUENT Drug, CARDIOVASCULAR2019
2019-10-01ABBVIE INC.$6,940Research paymentCash or cash equivalentM18-9182019
2019-09-23ABBVIE INC.$18,874Research paymentCash or cash equivalentM18-9182019
2019-09-16ABBVIE INC.$7,500Research paymentCash or cash equivalentM18-9182019
2019-09-16Takeda Pharmaceuticals U.S.A., Inc.$3,747Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-08-21ABBVIE INC.$3,721Research paymentCash or cash equivalentM18-9182019
2019-08-05Takeda Pharmaceuticals U.S.A., Inc.$14,988Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-08-05Takeda Pharmaceuticals U.S.A., Inc.$3,747Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-08-05Takeda Pharmaceuticals U.S.A., Inc.$2,000Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-07-15Takeda Pharmaceuticals U.S.A., Inc.$1,585Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-07-11ABBVIE INC.$540Research paymentCash or cash equivalentM14-2222019
2019-07-11ABBVIE INC.$448Research paymentCash or cash equivalentM14-2222019
2019-06-27ABBVIE INC.$325Research paymentCash or cash equivalentCreon Drug, EndocrinologyP12-7922019
2019-06-17Takeda Pharmaceuticals U.S.A., Inc.$5,089Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-06-17Takeda Pharmaceuticals U.S.A., Inc.$3,119Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-05-23ABBVIE INC.$302Research paymentCash or cash equivalentM14-2222019
2019-04-26SANOFI-AVENTIS U.S. LLC$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentPRALUENT Drug, CARDIOVASCULAR2019
2019-04-22Takeda Pharmaceuticals U.S.A., Inc.$14,988Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-04-22Takeda Pharmaceuticals U.S.A., Inc.$243Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-04-18Celgene Corporation$2,225Research paymentCash or cash equivalentRevlimid Drug, Hematology / OncologyCelgene - Connect MDSAML2019
2019-04-15GENZYME CORPORATION$563Research paymentCash or cash equivalentLEMTRADA Drug, MULTIPLE SCLEROSISA Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS0342019
2019-03-23Olympus America Inc.$36GiftIn-kind items and services Device, GI & Respiratory Products2019
2019-03-23Olympus America Inc.$17GiftIn-kind items and services2019
2019-03-23Olympus America Inc.$11GiftIn-kind items and servicesOlympus Capital Accessories Device, ENT Products2019
2019-03-18Takeda Pharmaceuticals U.S.A., Inc.$1,802Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-03-08ABBVIE INC.$3,449Research paymentCash or cash equivalentM15-5662019
2019-03-07ABBVIE INC.$2,940Research paymentCash or cash equivalentM15-5662019
2019-02-28ABBVIE INC.$6,544Research paymentCash or cash equivalentM14-2222019
2019-02-22Celgene Corporation$3,375Research paymentCash or cash equivalentRevlimid Drug, Hematology / OncologyCelgene - Connect MDSAML2019
2019-02-14ABBVIE INC.$4,420Research paymentCash or cash equivalentM15-5662019
2019-02-14Allergan, Inc.$1,392Research paymentCash or cash equivalentZENPEP Drug, CYSTIC FIBROSISLONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR2019
2019-02-14ABBVIE INC.$1,308Research paymentCash or cash equivalentCreon Drug, EndocrinologyP12-7922019
2019-02-11Takeda Pharmaceuticals U.S.A., Inc.$1,240Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019
2019-02-05Janssen Pharmaceuticals, Inc$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentXARELTO Drug, Cardiovascular & Metabolism2019
2019-01-14Takeda Pharmaceuticals U.S.A., Inc.$1,827Research paymentCash or cash equivalentA phase 2, randomized study of MLN0128 -a dual TORC1-2 inhibitor-, MLN0128 - MLN1117 -a PI3Ka inhibitor-, weekly paclita2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Sonoma CountySanta Rosa city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Santa Rosa, CA, county Sonoma County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Santa Rosa, CA
County
Sonoma County, CA
State
California
Population B01003177,090485,04039,287,377
Population, 2020 census P1178,127488,86339,538,223
Median age B0100241.242.937.9
Under 18 B0100120.1%19.0%22.0%
65 and over B0100119.0%21.5%15.7%
Households B1100168,321190,99813,548,091
Foreign born B0500221.2%16.8%27.0%
Median household income B19013$99,060$104,674$99,122
Median family income B19113$120,944$126,900$113,346
Per capita income B19301$52,066$56,640$49,513
Poverty rate B170019.7%8.9%12.0%
Unemployment rate B230256.3%5.7%6.6%
Civilian labor force B2302596,710258,15520,068,466
Mean commute (minutes) B0801322.925.128.7
Bachelor's degree or higher B1500335.1%38.5%37.1%
Housing units B2500171,382207,69914,644,735
Owner-occupied B2500356.7%62.6%55.9%
Renters B2500343.3%37.4%44.1%
Median home value B25077$713,900$815,500$734,700
Median gross rent B25064$2,152$2,158$2,036
White, not Hispanic B0300248.7%57.9%33.8%
Black B030021.9%1.5%5.2%
Hispanic or Latino B0300237.4%30.0%40.2%
Asian B030026.3%4.3%15.3%
American Indian and Alaska Native B030020.3%0.3%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santa Rosa, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.